B
Bernard Masereel
Researcher at Université de Namur
Publications - 186
Citations - 6688
Bernard Masereel is an academic researcher from Université de Namur. The author has contributed to research in topics: Thromboxane-A synthase & Thromboxane. The author has an hindex of 42, co-authored 185 publications receiving 6181 citations. Previous affiliations of Bernard Masereel include Université libre de Bruxelles & University of Liège.
Papers
More filters
Journal ArticleDOI
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte,Pierre Larrieu,Vincent Stroobant,Didier Colau,Eduard Dolusic,Raphaël Frédérick,Etienne De Plaen,Catherine Uyttenhove,Johan Wouters,Bernard Masereel,Benoît Van den Eynde +10 more
TL;DR: A TDO inhibitor was developed, which, upon systemic treatment, restored the ability of mice to reject TDO-expressing tumors and established proof-of-concept for the use of TDO inhibitors in cancer therapy.
Journal ArticleDOI
An overview of inhibitors of Na(+)/H(+) exchanger.
TL;DR: Extensive pre-clinical studies indicated that NHE inhibitors afford substantial protection in different animal models of myocardial ischemia (MI) and reperfusion, but the results of clinical trials involving eniporide and cariporides were mixed.
Journal Article
Reversal of Tumoral Immune Resistance by Inhibition of Tryptophan 2,3-Dioxygenase (TDO): Design, Synthesis and Preclinical Evaluation of a Novel TDO Inhibitor.
Eduard Dolusic,Pierre Larrieu,Laurence Moineaux,Vincent Stroobant,Luc Pilotte,Didier Colaux,Benoît Van den Eynde,Bernard Masereel,Johan Wouters,Raphaël Frédérick +9 more
TL;DR: In this paper, the authors showed that enzymatically active Tryptophan 2,3-dioxygenase (TDO) is expressed in a significant proportion of human tumors and developed a TDO inhibitor which, upon systemic treatment, restored the ability of mice to reject TDO-expressing tumors.
Journal ArticleDOI
Targeting tumor-associated carbonic anhydrase IX in cancer therapy
TL;DR: Selective CA IX inhibitors could prove useful for elucidating the role of CA IX in hypoxic cancers, for controlling the pH imbalance in tumor cells and for developing diagnostic or therapeutic applications for tumor management.
Journal ArticleDOI
Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins.
Alfonso Maresca,Claudia Temperini,Lionel Pochet,Bernard Masereel,Andrea Scozzafava,Claudiu T. Supuran +5 more
TL;DR: A new series of variously substituted coumarins and a thiocoumarin for their interaction with 13 mammalian CA isoforms, detecting low nanomolar and isoform selective inhibitors, afford isoform-selective CAIs with various biomedical applications, which render these classes of compounds superior to the clinically used sulfonamides.